ACAD - Latest News

ACADIA Pharmaceuticals Inc. (ACAD), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $4.34B. Trailing twelve-month P/E ratio is 11.49. Beta to the broader market is 0.83.

The article list below shows the most recent ACAD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ACAD Headlines

ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome

zacks.com - Jun 29, 2026

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming mo

Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus

seekingalpha.com - Jun 29, 2026

Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europ

Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?

zacks.com - Jun 29, 2026

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the

Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy

benzinga.com - Jun 26, 2026

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the Europe

Why Acadia Pharmaceuticals Stock Is Soaring Today

fool.com - Jun 26, 2026

Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition t

How News Affects ACAD Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ACAD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ACAD news questions

What is the latest ACAD news headline?

The most recent ACAD headline (Jun 29, 2026) is "ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ACAD news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ACAD news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ACAD options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.